Select the Abstracts by Number

Click    to view the poster

301   Susceptibility of Simian Immunodeficiency Virus (SIV) and Simian-Human Immunodeficiency Virus (SHIV) to Various Anti-HIV Compounds: Implications for Postexposure Prophylaxis.

302   In VitroandIn VivoPre- Clinical Analyses of the Antiretroviral Drug Candidate 4- Methyl Dicamphanoyl Khellactone.

303   ACH-126,443: A New Nucleoside Analog with Potent Activity against Wild-Type and Resistant HIV-1 and a Promising Pharmacokinetic and Mitochondrial Safety Profile.

304   TMC120 (R147681), a Next-Generation NNRTI, Has Potent In Vitro Activity Against NNRTI-Resistant HIV Variants.

305   4´-Ethynyl Nucleoside Analogs: Potent Inhibitors Active against Multi-Drug-Resistant HIV Variants In Vitro.

306   Mechanistic Studies of Dioxolane Guanosine 5´- Triphosphate: Implications for Efficacy, Lack of Cross- Resistance and Selectivity of DAPD.

307   Low Concentrations of Mycophenolic Acid Augment the Antiretroviral Activity of Abacavir (ABC), Didanosine (DDI), Tenofovir (TFV), and the Combination of ABC and DDI In Vitro.

308   A Highly Synergistic Tripe Antiviral Combination with Potential Activity against Both HIV and Hepatitis C Viruses.

309   New Small-Molecule Inhibitors of HIV-1 Entry.

310   Mechanisms of Synergy Between HIV-1 Attachment, Coreceptor and Fusion Inhibitors.

311   Coreceptor Trap Therapy: Combination of CCR5 and CXCR4 Inhibitors Blocks Human Immunodeficiency Virus Type I Infection In Vivo.

312   Gene Delivery Protects from HIV-1In Vivo.

313   The Binding Subunit of Pertussis Toxin Is a Potent Broad-Spectrum Inhibitor of R5 and X4 HIV-1 Replication.